$334 Million is the total value of DAFNA Capital Management LLC's 72 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PHAS | Exit | PHASEBIO PHARMACEUTICALS INC | $0 | – | -321,856 | -100.0% | -0.00% | – |
BDTX | Exit | BLACK DIAMOND THERAPEUTICS I | $0 | – | -97,500 | -100.0% | -0.05% | – |
SCYX | Exit | SCYNEXIS INC | $0 | – | -153,269 | -100.0% | -0.07% | – |
MGNX | Exit | MACROGENICS INC | $0 | – | -39,879 | -100.0% | -0.08% | – |
BMEA | Exit | BIOMEA FUSION INC | $0 | – | -34,625 | -100.0% | -0.08% | – |
Exit | CINCOR PHARMA INC | $0 | – | -48,000 | -100.0% | -0.17% | – | |
AFMD | Exit | AFFIMED N V | $0 | – | -686,282 | -100.0% | -0.24% | – |
CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -171,059 | -100.0% | -0.30% | – |
FSTX | Exit | F-STAR THERAPEUTICS INC | $0 | – | -576,881 | -100.0% | -1.03% | – |
ETNB | Exit | 89BIO INC | $0 | – | -324,173 | -100.0% | -1.16% | – |
FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -550,940 | -100.0% | -1.57% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
ATRICURE INC | 42 | Q3 2023 | 11.4% |
MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.